What we found on the web about Gleevec
Imatinib - Wikipedia, the free encyclopedia
Imatinib is a drug used to treat certain types of cancer. It is currently marketed by Novartis as Gleevec or Glivec (Europe / Australia) as its mesylate salt, imatinib mesilate ...
Philadelphia chromosome - Wikipedia, the free encyclopedia
In the late 1990s, STI-571 (imatinib, Gleevec/Glivec) was identified by Novartis pharmaceuticals in high-throughput screens for tyrosine kinase inhibitors.
Gleevec Tablets (Novartis), Drug Reference Encyclopedia
Gleevec Tablets (Novartis), Drug Reference Encyclopedia - Physicians PDR ... Gleevec® (imatinib mesylate) film-coated tablets contain imatinib mesylate ...
imatinib (Gleevec)
In children, Gleevec treatment can be given as a once-daily dose or ... In the clinical study, Gleevec was administered for one year. ... Gleevec is not known. ...
Gleevec, Imatinib Mesylate, Glivec - Chemotherapy Drugs, Chemo Drug ...
Gleevec is the trade name for Imatinib Mesylate. Glivec and STI-571 are other names for Imatinib Mesylate. Gleevec is a targeted therapy. It is classified as a signal transduction ...
Gleevec
Gleevec is the brand name given to the drug Imatinib in the United States. ... Some side effects of Gleevec include bleeding, bloating, abdominal pain, body ...
FAQ
Is Gleevec (STI571) available in any Country other than the United States for ... Mayfield) have any special influence which might help me get Gleevec (STI571) ...
IMATINIB - ORAL (Gleevec) side effects, medical uses, and ...
Consumer information about the medication IMATINIB - ORAL (Gleevec), includes side effects, drug interactions, recommended dosages, and storage information. Read ...
GLEEVEC® Safety Information | My CML Circle™
GLEEVEC® (imatinib mesylate) tablets are indicated for the treatment of newly diagnosed adult patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in ...
What dose Gleevec is best?
The Life Raft Group. A patient/caregiver support group for GIST cancer. ... Gleevec is metabolized in the liver by at least two enzymes, CYP3A4 (primary) ...
ACS :: Gleevec Emerges as One of 2001's Top Advances in Cancer
Gleevec, made by Novartis, is a new type of oral cancer drug that works by ... Experts warn that Gleevec is no magic bullet, but that it holds much promise not ...
Gleevec - Drug information from MediLexicon
Drug information and side-effects for Gleevec ... Possible similar drugs: Gleevec ... Gleevec has been approved for treatment of patients with chronic myeloid ...
Imatinib - Wikipedia, the free encyclopedia
Imatinib is a drug used to treat certain types of cancer. It is currently marketed by Novartis as Gleevec or Glivec (Europe / Australia) as its mesylate salt, imatinib mesilate ...
Entry added by Creative Administrator
Creative Administrator also edited:
Here is what users have to say about Gleevec

Imatinib is a drug used to treat certain types of cancer. It is currently marketed by Novartis as Gleevec (USA) or Glivec (Europe/Australia) as its mesylate salt, imatinib mesilate (INN). It was originally coded during development as CGP57148B or STI-571 (these terms are used in early preclinical publications). It is used in treating chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GISTs) and a number of other malignancies.

Welcome to CWAnswers

CWAnswers is your guide to the sprawling world wide web. The directory aims to provide a useful guide made by users. You can share your knowledge as well - simply register and edit your first entry. For questions just contact the team at support - at - cwanswers.com.

Weblinks

Top 10

Things you find nowhere else.

Comments

You must be logged in to post a comment.

No comments yet on this topic. Be the first one!
These recent articles mention Gleevec
Synta Presents Preclinical Data on Next Generation Hsp90 Inhibitor, STA-9090
Business Wire via Yahoo! Finance
LEXINGTON, Mass.----Synta Pharmaceuticals Corp. , a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that preclinical data presented a...
Prolonged exposure to formaldehyde linked with increased risk of myeloid leukemia
News-Medical-Net
Long durations of exposure to formaldehyde used for embalming in the funeral industry were associated with an increased risk of death from myeloid leukemia, according to a new study published online November 20 in the Journal of the Nationa...
University of California Los Angeles Selects Velos eResearch
PR Newswire
A few of the more well-known therapies include: Herceptin, a targeted breast cancer drug and the first approved treatment that attacks cancer at its genetic root; Gleevec, a once-a-day pill that targets a common form of adult leukemia calle...
Novartis Profit Beats Estimates; Shares Rise (Update1)
Bloomberg
Increased revenue from the hypertension drug Diovan and the cancer treatment Gleevec countered some of the effect from currency shifts. Chief Executive Officer Daniel Vasella confirmed the company’s forecast and said 2009 profit may fall be...
Novartis posts 14 percent drop in Q1 profit
AOL
Analysts at Zuercher Kantonalbank gave Novartis a "slightly positive rating." They said the pharma division was showing strength again but that its sales of blood-pressure drug Diovan and its best-selling anticancer drug Glivec — known as G...
Pipeline Insight - Hematological Malignancies Companies target niche ...
PR Inside
... drugs are in late-phase studies and are forecast to achieve peak sales of $3.5 billion in 2018. Drug developers are keen to replicate the success of the two blockbusters: Biogen Idec/Genentech/Roche´s Rituxan (rituximab) and Novartis´s...
The Next Cancer Bestseller?
Forbes
Novartis hit a $3.7 billion (annual sales) home run with its leukemia drug Gleevec, launched in 2001. Now it hopes Afinitor will be its next cancer bestseller, says David Epstein, who leads Novartis' cancer drug business. It was approved in...